Product logins

Find logins to all Clarivate products below.


Ponatinib Hydrochloride

ICLUSIG®

About ICLUSIG®

  • Marketed by Takeda Pharmaceutical Company Limited
  • Orally bioavailable Bcr-Abl tyrosine kinase inhibitor
  • Treatment of adult patients with treatment-resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML), accelerated phase (AP) or blast phase (BP) CML or Philadelphia chromosome–positive (Ph+) CML for which no other kinase inhibitors are indicated, and T315I-positive CML or T315I-positive Ph+ ALL

Review and approval status

December 14, 2012

First U.S. approval

July 1, 2013

First E.U. approval

Actual and expected launch:

  • 2026: Patent expiry: United States
  • 2027: Patent expiry: Japan
  • 2028: SPC expiry: European Union

API availability